| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oligonucleotide Array Sequence Analysis | 7 | 2019 | 320 | 2.320 |
Why?
|
| In Situ Hybridization, Fluorescence | 19 | 2023 | 144 | 2.210 |
Why?
|
| DNA Copy Number Variations | 4 | 2020 | 27 | 1.860 |
Why?
|
| Kidney Neoplasms | 7 | 2020 | 206 | 1.770 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2020 | 110 | 1.640 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2021 | 44 | 1.600 |
Why?
|
| Translocation, Genetic | 5 | 2020 | 73 | 1.580 |
Why?
|
| Loss of Heterozygosity | 5 | 2023 | 25 | 1.480 |
Why?
|
| Microarray Analysis | 5 | 2021 | 63 | 1.270 |
Why?
|
| Genomics | 6 | 2021 | 167 | 1.200 |
Why?
|
| Chromosome Aberrations | 9 | 2016 | 86 | 1.150 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2023 | 116 | 1.130 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2021 | 627 | 1.040 |
Why?
|
| Chromosomes, Human | 1 | 2021 | 14 | 0.880 |
Why?
|
| Clone Cells | 1 | 2021 | 67 | 0.880 |
Why?
|
| Neoplasms | 6 | 2021 | 1660 | 0.860 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 47 | 0.850 |
Why?
|
| Sequence Analysis, DNA | 3 | 2019 | 208 | 0.840 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 231 | 0.840 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2020 | 4 | 0.820 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2020 | 23 | 0.810 |
Why?
|
| Myeloproliferative Disorders | 1 | 2020 | 11 | 0.810 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2020 | 18 | 0.810 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 40 | 0.810 |
Why?
|
| Eosinophilia | 1 | 2020 | 47 | 0.780 |
Why?
|
| Prognosis | 7 | 2023 | 2093 | 0.770 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 438 | 0.770 |
Why?
|
| Cytogenetic Analysis | 3 | 2015 | 12 | 0.770 |
Why?
|
| Genetic Testing | 6 | 2020 | 159 | 0.720 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 70 | 0.710 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 4 | 2020 | 8 | 0.690 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2021 | 10 | 0.670 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2013 | 138 | 0.670 |
Why?
|
| Genetics, Medical | 4 | 2021 | 17 | 0.660 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2017 | 47 | 0.650 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2007 | 41 | 0.600 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2006 | 32 | 0.590 |
Why?
|
| Mutation | 6 | 2023 | 1213 | 0.550 |
Why?
|
| Humans | 56 | 2023 | 68502 | 0.540 |
Why?
|
| Genome, Human | 4 | 2021 | 62 | 0.510 |
Why?
|
| Genes, erbB-2 | 3 | 2007 | 15 | 0.460 |
Why?
|
| Karyotyping | 6 | 2021 | 74 | 0.460 |
Why?
|
| Mitochondrial Diseases | 1 | 2011 | 24 | 0.430 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2011 | 35 | 0.420 |
Why?
|
| DNA, Mitochondrial | 1 | 2011 | 84 | 0.420 |
Why?
|
| Turner Syndrome | 1 | 2010 | 10 | 0.390 |
Why?
|
| Chromosomes, Human, X | 1 | 2010 | 24 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2007 | 28 | 0.390 |
Why?
|
| Proto-Oncogenes | 2 | 2007 | 37 | 0.360 |
Why?
|
| Cystic Fibrosis | 3 | 2014 | 283 | 0.360 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2006 | 51 | 0.350 |
Why?
|
| Cytomegalovirus | 1 | 2009 | 63 | 0.350 |
Why?
|
| Viral Load | 1 | 2009 | 127 | 0.350 |
Why?
|
| Laboratories | 4 | 2019 | 44 | 0.350 |
Why?
|
| Cytomegalovirus Infections | 1 | 2009 | 69 | 0.340 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2020 | 32 | 0.340 |
Why?
|
| Breast Neoplasms | 5 | 2016 | 1531 | 0.330 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 492 | 0.330 |
Why?
|
| Hematologic Diseases | 1 | 2007 | 20 | 0.320 |
Why?
|
| Gene Dosage | 4 | 2021 | 47 | 0.320 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2017 | 68 | 0.320 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2007 | 37 | 0.320 |
Why?
|
| Cytogenetics | 2 | 2006 | 7 | 0.310 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 11 | 0.310 |
Why?
|
| Mitochondria | 1 | 2011 | 642 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2005 | 10 | 0.290 |
Why?
|
| Quality Control | 1 | 2005 | 81 | 0.290 |
Why?
|
| Congenital Abnormalities | 1 | 2005 | 42 | 0.280 |
Why?
|
| Receptor, ErbB-2 | 3 | 2016 | 128 | 0.280 |
Why?
|
| Gene Deletion | 1 | 2006 | 235 | 0.280 |
Why?
|
| Chromosome Banding | 5 | 2008 | 24 | 0.270 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 19 | 0.270 |
Why?
|
| Female | 25 | 2021 | 37990 | 0.270 |
Why?
|
| Transcriptional Regulator ERG | 2 | 2023 | 7 | 0.260 |
Why?
|
| Homozygote | 3 | 2017 | 119 | 0.250 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 698 | 0.250 |
Why?
|
| Nephrosis | 1 | 2022 | 6 | 0.240 |
Why?
|
| Microcephaly | 1 | 2022 | 6 | 0.240 |
Why?
|
| Hernia, Hiatal | 1 | 2022 | 18 | 0.240 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2015 | 24 | 0.230 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 15 | 0.230 |
Why?
|
| Male | 18 | 2021 | 37252 | 0.230 |
Why?
|
| Middle Aged | 10 | 2021 | 21116 | 0.230 |
Why?
|
| DNA Mutational Analysis | 2 | 2017 | 159 | 0.230 |
Why?
|
| Genomic Instability | 1 | 2021 | 41 | 0.210 |
Why?
|
| Reproducibility of Results | 6 | 2015 | 2077 | 0.210 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2021 | 37 | 0.210 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2021 | 33 | 0.200 |
Why?
|
| Transcription Factors | 1 | 2005 | 754 | 0.200 |
Why?
|
| Frameshift Mutation | 1 | 2019 | 8 | 0.190 |
Why?
|
| Retinal Dystrophies | 1 | 2019 | 4 | 0.190 |
Why?
|
| Leber Congenital Amaurosis | 1 | 2019 | 7 | 0.190 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 1752 | 0.180 |
Why?
|
| cis-trans-Isomerases | 1 | 2019 | 63 | 0.180 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 1139 | 0.180 |
Why?
|
| Endolymphatic Sac | 1 | 2018 | 6 | 0.180 |
Why?
|
| Mosaicism | 2 | 2011 | 21 | 0.180 |
Why?
|
| Ear Neoplasms | 1 | 2018 | 13 | 0.180 |
Why?
|
| Paraffin Embedding | 1 | 2019 | 47 | 0.180 |
Why?
|
| Tissue Fixation | 1 | 2019 | 58 | 0.180 |
Why?
|
| Gene Amplification | 3 | 2007 | 71 | 0.170 |
Why?
|
| Mutation, Missense | 1 | 2019 | 112 | 0.170 |
Why?
|
| Genotype | 3 | 2011 | 784 | 0.170 |
Why?
|
| Waardenburg Syndrome | 1 | 2017 | 5 | 0.170 |
Why?
|
| SOXE Transcription Factors | 1 | 2017 | 9 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2017 | 12 | 0.170 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 43 | 0.170 |
Why?
|
| Aged | 7 | 2021 | 14841 | 0.170 |
Why?
|
| Disease Progression | 1 | 2021 | 1037 | 0.170 |
Why?
|
| Prenatal Diagnosis | 1 | 2017 | 73 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 444 | 0.160 |
Why?
|
| Urologic Neoplasms | 1 | 2016 | 14 | 0.160 |
Why?
|
| Chromothripsis | 1 | 2016 | 2 | 0.150 |
Why?
|
| Genomic Imprinting | 1 | 2016 | 10 | 0.150 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2016 | 15 | 0.150 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 62 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2015 | 18 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 307 | 0.150 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 57 | 0.150 |
Why?
|
| Pulmonary Veins | 1 | 2016 | 56 | 0.150 |
Why?
|
| Karyotype | 1 | 2015 | 7 | 0.150 |
Why?
|
| Lipoma | 1 | 2015 | 24 | 0.140 |
Why?
|
| Standard of Care | 1 | 2015 | 22 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 22 | 0.140 |
Why?
|
| Hemangioma | 1 | 2015 | 51 | 0.140 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 142 | 0.140 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 273 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 508 | 0.140 |
Why?
|
| Tissue Donors | 1 | 2016 | 195 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 2 | 2005 | 177 | 0.130 |
Why?
|
| Cytodiagnosis | 1 | 2013 | 20 | 0.120 |
Why?
|
| Urine | 1 | 2013 | 47 | 0.120 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1172 | 0.120 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2012 | 1 | 0.110 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2012 | 72 | 0.110 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2011 | 3 | 0.110 |
Why?
|
| Interphase | 2 | 2012 | 19 | 0.110 |
Why?
|
| DNA Polymerase gamma | 1 | 2011 | 12 | 0.110 |
Why?
|
| Adult | 8 | 2018 | 21373 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2012 | 92 | 0.110 |
Why?
|
| Phenotype | 3 | 2017 | 946 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2021 | 7263 | 0.100 |
Why?
|
| Fluorescent Dyes | 1 | 2012 | 191 | 0.100 |
Why?
|
| Pregnancy | 3 | 2017 | 2329 | 0.100 |
Why?
|
| Monosomy | 1 | 2010 | 6 | 0.100 |
Why?
|
| Societies, Medical | 3 | 2011 | 403 | 0.100 |
Why?
|
| Cell Nucleus | 2 | 2012 | 305 | 0.100 |
Why?
|
| Fetal Death | 1 | 2010 | 49 | 0.100 |
Why?
|
| Ovary | 1 | 2010 | 99 | 0.090 |
Why?
|
| Bone Marrow Cells | 2 | 2011 | 217 | 0.090 |
Why?
|
| United States | 6 | 2021 | 7333 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 369 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2008 | 9 | 0.090 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 163 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 2008 | 41 | 0.090 |
Why?
|
| Polyploidy | 1 | 2008 | 24 | 0.090 |
Why?
|
| Kidney Transplantation | 1 | 2016 | 839 | 0.090 |
Why?
|
| Polymorphism, Genetic | 2 | 2006 | 301 | 0.080 |
Why?
|
| Molecular Probes | 1 | 2007 | 27 | 0.080 |
Why?
|
| Linear Models | 1 | 2009 | 521 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2011 | 400 | 0.080 |
Why?
|
| Azure Stains | 1 | 2006 | 4 | 0.080 |
Why?
|
| Base Sequence | 2 | 2006 | 1015 | 0.080 |
Why?
|
| DNA | 1 | 2009 | 597 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 1447 | 0.070 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 201 | 0.070 |
Why?
|
| Prothrombin | 1 | 2005 | 12 | 0.070 |
Why?
|
| Cell Division | 1 | 2007 | 541 | 0.070 |
Why?
|
| Artificial Gene Fusion | 1 | 2005 | 2 | 0.070 |
Why?
|
| Alleles | 1 | 2006 | 386 | 0.070 |
Why?
|
| Government Regulation | 1 | 2005 | 46 | 0.070 |
Why?
|
| Factor V | 1 | 2005 | 20 | 0.070 |
Why?
|
| Incidence | 1 | 2010 | 1581 | 0.070 |
Why?
|
| Leukocytes | 1 | 2005 | 99 | 0.070 |
Why?
|
| Extraembryonic Membranes | 1 | 2004 | 10 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2019 | 3185 | 0.070 |
Why?
|
| Wilms Tumor | 1 | 2004 | 47 | 0.070 |
Why?
|
| Bottle-Nosed Dolphin | 1 | 2005 | 86 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2005 | 91 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2005 | 189 | 0.070 |
Why?
|
| Trisomy | 1 | 2004 | 47 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 772 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 614 | 0.070 |
Why?
|
| Child | 3 | 2019 | 6400 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 3256 | 0.060 |
Why?
|
| Keratins | 2 | 2018 | 48 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 710 | 0.060 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2003 | 9 | 0.060 |
Why?
|
| Cation Transport Proteins | 1 | 2003 | 11 | 0.060 |
Why?
|
| Long QT Syndrome | 1 | 2003 | 14 | 0.060 |
Why?
|
| Neuropathology | 1 | 2022 | 5 | 0.060 |
Why?
|
| Calcinosis | 1 | 2004 | 241 | 0.060 |
Why?
|
| Potassium Channels | 1 | 2003 | 55 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 475 | 0.060 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 18 | 0.060 |
Why?
|
| Infant | 2 | 2020 | 2891 | 0.060 |
Why?
|
| Fatal Outcome | 2 | 2017 | 164 | 0.060 |
Why?
|
| Reference Standards | 2 | 2017 | 115 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2003 | 237 | 0.050 |
Why?
|
| Genes, Neoplasm | 1 | 2021 | 18 | 0.050 |
Why?
|
| Pedigree | 2 | 2016 | 159 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 4842 | 0.050 |
Why?
|
| Young Adult | 3 | 2018 | 5708 | 0.050 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2020 | 6 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2022 | 270 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2020 | 51 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2020 | 23 | 0.050 |
Why?
|
| Founder Effect | 1 | 2019 | 5 | 0.050 |
Why?
|
| Costa Rica | 1 | 2019 | 6 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 756 | 0.050 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2019 | 31 | 0.050 |
Why?
|
| PAX2 Transcription Factor | 1 | 2018 | 11 | 0.050 |
Why?
|
| Electroretinography | 1 | 2019 | 122 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2016 | 2453 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 2220 | 0.040 |
Why?
|
| Autopsy | 1 | 2017 | 56 | 0.040 |
Why?
|
| Abnormalities, Multiple | 2 | 2011 | 109 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2017 | 144 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 122 | 0.040 |
Why?
|
| Data Collection | 2 | 2011 | 420 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2017 | 14 | 0.040 |
Why?
|
| Computational Biology | 1 | 2018 | 189 | 0.040 |
Why?
|
| BK Virus | 1 | 2016 | 17 | 0.040 |
Why?
|
| Polyomavirus Infections | 1 | 2016 | 17 | 0.040 |
Why?
|
| Retina | 1 | 2019 | 252 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2017 | 52 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 2016 | 32 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2016 | 7 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 287 | 0.040 |
Why?
|
| Genes, Lethal | 1 | 2016 | 16 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2016 | 18 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1173 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 242 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2016 | 89 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 1848 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 94 | 0.040 |
Why?
|
| Neck | 1 | 2015 | 62 | 0.040 |
Why?
|
| Adolescent | 2 | 2019 | 8903 | 0.040 |
Why?
|
| Prevalence | 1 | 2019 | 1609 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 866 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2013 | 23 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 110 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2012 | 16 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2012 | 15 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 515 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 2356 | 0.030 |
Why?
|
| Chimerism | 1 | 2011 | 4 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 131 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2011 | 10 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2011 | 68 | 0.030 |
Why?
|
| Cell Line | 2 | 2005 | 1751 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2011 | 119 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 714 | 0.020 |
Why?
|
| Software | 1 | 2013 | 419 | 0.020 |
Why?
|
| Intellectual Disability | 1 | 2011 | 114 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 265 | 0.020 |
Why?
|
| Skin | 1 | 2011 | 451 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1857 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2006 | 93 | 0.020 |
Why?
|
| Spectral Karyotyping | 1 | 2005 | 4 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2323 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2005 | 100 | 0.020 |
Why?
|
| Genetic Services | 1 | 2005 | 1 | 0.020 |
Why?
|
| Epidermis | 1 | 2005 | 42 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 2004 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 562 | 0.020 |
Why?
|
| Environmental Monitoring | 1 | 2005 | 180 | 0.020 |
Why?
|
| Age Distribution | 1 | 2005 | 319 | 0.020 |
Why?
|
| Introns | 1 | 2004 | 68 | 0.020 |
Why?
|
| Threonine | 1 | 2004 | 47 | 0.020 |
Why?
|
| Transfection | 1 | 2005 | 782 | 0.020 |
Why?
|
| ERG1 Potassium Channel | 1 | 2003 | 2 | 0.020 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2003 | 3 | 0.020 |
Why?
|
| Proteomics | 1 | 2005 | 246 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2003 | 196 | 0.010 |
Why?
|
| Family Health | 1 | 2003 | 83 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 5718 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 785 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2003 | 601 | 0.010 |
Why?
|
| South Carolina | 1 | 2005 | 2750 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 2798 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1852 | 0.010 |
Why?
|
| Animals | 1 | 2005 | 20811 | 0.010 |
Why?
|